Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial-Reference-Cited by-同舟云学术

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

Published:2013-09 Issue:10 Volume:14 Page:953-961
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Shi Yuankai,Zhang Li,Liu Xiaoqing,Zhou Caicun,Zhang Li,Zhang Shucai,Wang Dong,Li Qiang,Qin Shukui,Hu Chunhong,Zhang Yiping,Chen Jianhua,Cheng Ying,Feng Jifeng,Zhang Helong,Song Yong,Wu Yi-Long,Xu Nong,Zhou Jianying,Luo Rongcheng,Bai Chunxue,Jin Yening,Liu Wenchao,Wei Zhaohui,Tan Fenlai,Wang Yinxiang,Ding Lieming,Dai Hong,Jiao Shunchang,Wang Jie,Liang Li,Zhang Weimin,Sun Yan

Funder

Key Special Program for Innovative Drugs

863 Project

Zhejiang Provincial Key Special Program

Publisher

Elsevier BV

Subject

Oncology

Reference28 articles.

1. Cancer statistics, 2012;Siegel;CA Cancer J Clin,2012

2. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005

3. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial;Kim;Lancet,2008